Analysts See $1.65 EPS for Omnicom Group Inc. (OMC); Regulus Therapeutics (RGLS) Sentiment Is 0.42

Omnicom Group Inc. (NYSE:OMC) Logo

Regulus Therapeutics Inc (RGLS) investors sentiment decreased to 0.42 in 2018 Q3. It’s down -0.26, from 0.68 in 2018Q2. The ratio has dropped, as 10 institutional investors increased or started new equity positions, while 24 sold and decreased their positions in Regulus Therapeutics Inc. The institutional investors in our database now hold: 36.23 million shares, down from 49.70 million shares in 2018Q2. Also, the number of institutional investors holding Regulus Therapeutics Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 14 Reduced: 10 Increased: 5 New Position: 5.

Analysts expect Omnicom Group Inc. (NYSE:OMC) to report $1.65 EPS on February, 21.They anticipate $0.10 EPS change or 6.45% from last quarter’s $1.55 EPS. OMC’s profit would be $369.79M giving it 11.13 P/E if the $1.65 EPS is correct. After having $1.24 EPS previously, Omnicom Group Inc.’s analysts see 33.06% EPS growth. The stock decreased 0.81% or $0.6 during the last trading session, reaching $73.49. About 3.42M shares traded or 46.54% up from the average. Omnicom Group Inc. (NYSE:OMC) has risen 3.76% since February 14, 2018 and is uptrending. It has outperformed by 3.76% the S&P500. Some Historical OMC News: 27/03/2018 – OMNICOM HEALTH GROUP – ACQUIRED UNIT’S MANAGEMENT TEAM ALSO JOINS EMC, WITH TAKAO OZAWA BEING PROMOTED TO MANAGING DIRECTOR; 17/04/2018 – Omnicom 1Q Income Tax Expense Reduced by $13M; 09/05/2018 – TBWA\Chiat\Day New York Taps Al Merry for Executive Creative Director Role; 30/05/2018 – Sorrell plots comeback with new listed company after WPP exit; 16/05/2018 – The lnteger Group Announces Partnership with Argentina’s AVC Marketing; 27/03/2018 – OMNICOM HEALTH GROUP BUYS ELSEVIER’S PHARMA COMMUNICATIONS; 16/04/2018 – IRI and Omnicom Media Group Announce Preferred Partnership for Omnicom Media Group’s Annalect Data and Analytics Division; 17/04/2018 – Omnicom Closes Above 200-Day Moving Average: Technicals; 23/05/2018 – Porter Novelli enlisted to support The Economist’s Pride and Prejudice Event; 23/05/2018 – London Exchange: PRESS: WPP Loses USD400 Million HSBC Account To Omnicom – FT

Since October 18, 2018, it had 0 buys, and 4 selling transactions for $1.10 million activity. On Friday, October 19 the insider Nelson Jonathan B. sold $1.01 million. $37,924 worth of Omnicom Group Inc. (NYSE:OMC) was sold by Hewitt Dennis E.. $40,657 worth of Omnicom Group Inc. (NYSE:OMC) was sold by RICE LINDA JOHNSON.

Omnicom Group Inc., together with its subsidiaries, provides advertising, marketing, and corporate communications services. The company has market cap of $16.47 billion. The firm offers a range of services in the areas of advertising, customer relationship management, or CRM, public relations, and specialty communications. It has a 12.61 P/E ratio. The Company’s services comprise advertising, brand consultancy, content marketing, corporate social responsibility consulting, crisis communication, custom publishing, data analytics, database management, environmental design, financial/corporate business-to-business advertising, graphic arts/digital imaging, healthcare communications, and instore design services.

Investors sentiment decreased to 0.83 in Q3 2018. Its down 0.17, from 1 in 2018Q2. It dropped, as 49 investors sold Omnicom Group Inc. shares while 234 reduced holdings. 69 funds opened positions while 165 raised stakes. 226.63 million shares or 1.94% less from 231.12 million shares in 2018Q2 were reported. United Fire Grp invested in 0.07% or 3,000 shares. Paloma Prns Management stated it has 5,307 shares or 0.01% of all its holdings. Tiaa Cref Management Ltd Liability Co, a New York-based fund reported 478,590 shares. Private Capital Advisors Inc holds 16,000 shares or 0.4% of its portfolio. Longview (Guernsey) Limited invested in 6.97M shares or 2.34% of the stock. Fincl Bank Of Montreal Can reported 579,851 shares. Transamerica Financial Advisors invested in 0% or 122 shares. Nomura Asset Mngmt holds 35,615 shares or 0.02% of its portfolio. Janney Capital Mngmt Ltd Limited Liability Company invested in 9,716 shares. Eaton Vance Mgmt has invested 0.02% in Omnicom Group Inc. (NYSE:OMC). Busey Tru has invested 0.65% in Omnicom Group Inc. (NYSE:OMC). Moreover, Wilbanks Smith And Thomas Asset Lc has 0.02% invested in Omnicom Group Inc. (NYSE:OMC). Trustmark Financial Bank Department reported 0% in Omnicom Group Inc. (NYSE:OMC). Virtu Limited Liability Corporation invested in 23,059 shares. Mutual Of America Ltd Liability accumulated 28,977 shares.

Among 2 analysts covering Omnicom Group (NYSE:OMC), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Omnicom Group had 2 analyst reports since October 24, 2018 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Outperform” on Wednesday, February 13. Citigroup maintained Omnicom Group Inc. (NYSE:OMC) on Wednesday, October 24 with “Neutral” rating.

More notable recent Omnicom Group Inc. (NYSE:OMC) news were published by: Gurufocus.com which released: “First Eagle Investment Trims Omnicom, Microsoft Positions – GuruFocus.com” on February 13, 2019, also Bizjournals.com with their article: “Jim Beam launches ‘Raised Right’ ad campaign (Video) – Chicago Business Journal” published on February 13, 2019, Benzinga.com published: “12 Stocks To Watch For February 12, 2019 – Benzinga” on February 12, 2019. More interesting news about Omnicom Group Inc. (NYSE:OMC) were released by: Seekingalpha.com and their article: “Ad giants slip after Publicis revenue disappointment – Seeking Alpha” published on February 06, 2019 as well as Benzinga.com‘s news article titled: “Earnings Scheduled For February 12, 2019 – Benzinga” with publication date: February 12, 2019.

Analysts await Regulus Therapeutics Inc. (NASDAQ:RGLS) to report earnings on March, 6. They expect $-0.91 EPS, up 45.83% or $0.77 from last year’s $-1.68 per share. After $-1.18 actual EPS reported by Regulus Therapeutics Inc. for the previous quarter, Wall Street now forecasts -22.88% EPS growth.

More notable recent Regulus Therapeutics Inc. (NASDAQ:RGLS) news were published by: Seekingalpha.com which released: “Regulus up 33% premarket – Seeking Alpha” on October 23, 2018, also Seekingalpha.com with their article: “Regulus Therapeutics reverse splits shares 1:12 – Seeking Alpha” published on October 04, 2018, Seekingalpha.com published: “Regulus up 20% premarket on restructured Sanofi deal – Seeking Alpha” on November 06, 2018. More interesting news about Regulus Therapeutics Inc. (NASDAQ:RGLS) were released by: Seekingalpha.com and their article: “Regulus -48.4% as it slashes 60% of workforce to stretch cash – Seeking Alpha” published on July 05, 2018 as well as Seekingalpha.com‘s news article titled: “Regulus up 8% after hours on positive preclinical data on RGLS4326 – Seeking Alpha” with publication date: January 04, 2019.

Nea Management Company Llc holds 1.12% of its portfolio in Regulus Therapeutics Inc. for 10.99 million shares. Bvf Inc Il owns 13.69 million shares or 0.24% of their US portfolio. Moreover, Ascend Capital Llc has 0.01% invested in the company for 1.05 million shares. The Sweden-based Rhenman & Partners Asset Management Ab has invested 0.01% in the stock. Bank Of New York Mellon Corp, a New York-based fund reported 34,188 shares.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company has market cap of $8.93 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. It currently has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

Omnicom Group Inc. (NYSE:OMC) Institutional Positions Chart